Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

790
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
790
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

143
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
143
Heart Failure Drugs: β-Blockers01:22

Heart Failure Drugs: β-Blockers

657
β-adrenergic antagonists, commonly known as β-blockers, block the effects of sympathetic neurotransmitters such as noradrenaline (NA) and adrenaline (ADR). They have several beneficial effects in heart failure treatment. They reduce heart rate, the force of contraction, and cardiac muscle relaxation. They also slow the atrial-ventricular conduction rate and raise the threshold for arrhythmias. The concentration of β-blockers determines their effects on bronchodilation,...
657
Heart Failure Drugs: Diuretics01:22

Heart Failure Drugs: Diuretics

717
Heart failure and kidney perfusion are interconnected in a complex way. Reduced renal perfusion and venous congestion are two significant factors that contribute to renal dysfunction in heart failure. The kidneys, primarily responsible for fluid balance in the body, are adversely affected due to compromised cardiac output and increased venous pressure. In response to reduced renal perfusion, the kidneys activate neurohumoral mechanisms to restore balance. However, these mechanisms can be...
717
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

332
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
332
Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

164
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
164

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Walking on Collaterals: Unveiling Discrepancies in Gender-Based Variances in Peripheral Arterial Disease.

Cureus·2025
Same author

Unusual Presentation of De Winter's Sign Due to Bezold-Jarisch Reflex in a Patient With Severe Aortic Valve Stenosis.

Cureus·2024
Same author

Incidence of premature battery depletion in subcutaneous cardioverter-defibrillator patients: insights from a multicenter registry.

Journal of interventional cardiac electrophysiology : an international journal of arrhythmias and pacing·2023
Same author

University of Puerto Rico School of Medicine.

Academic medicine : journal of the Association of American Medical Colleges·2021
Same author

Insight on the Genetics of Atrial Fibrillation in Puerto Rican Hispanics.

Stroke research and treatment·2021
Same author

Use of Sublingual Nitrates for Management of Limb Ischemia Secondary to Inadvertent Intra-Arterial Buprenorphine/Naloxone (Suboxone®) Film Injection.

Puerto Rico health sciences journal·2020

Related Experiment Video

Updated: Dec 17, 2025

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.8K

Midodrine in end-stage heart failure.

Ariel Gonzalez-Cordero1,2, Stephanie Ortiz-Troche2, Juan Nieves-Rivera3

  • 1Internal Medicine Department, University of Puerto Rico, San Juan, Puerto Rico, Puerto Rico arielgonzalezcordero@gmail.com.

BMJ Supportive & Palliative Care
|June 26, 2020
PubMed
Summary

For end-stage heart failure patients with refractory hypotension, midodrine offers a potential alternative to intravenous vasopressors. This case study shows successful weaning from vasopressors, improving patient management.

Keywords:
end of life careheart failurehospice carehospital care

More Related Videos

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.6K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.3K

Related Experiment Videos

Last Updated: Dec 17, 2025

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach
07:49

Author Spotlight: Investigating HR-Dependent Cardiac Function in Mouse Models Through a Novel Atrial-Pacing Approach

Published on: July 21, 2023

1.8K
Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice
05:08

Implantation of an Isoproterenol Mini-Pump to Induce Heart Failure in Mice

Published on: October 3, 2019

11.6K
Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment
08:24

Establishing a Swine Model of Post-myocardial Infarction Heart Failure for Stem Cell Treatment

Published on: May 25, 2020

7.3K

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • End-stage heart failure (HF) affects 5% of patients, often requiring prolonged hospitalization and inotropic support.
  • Refractory hypotension is a significant challenge in advanced HF, limiting treatment options.
  • Advanced therapies like heart transplantation or ventricular assist devices are not suitable for all patients.

Observation:

  • A patient with end-stage HF and cardiogenic shock required prolonged intravenous vasopressor therapy for refractory hypotension.
  • The patient was ineligible for heart transplantation or left ventricular-assist device implantation.
  • Midodrine was administered as a salvage therapy to attempt vasopressor discontinuation.

Findings:

  • Midodrine therapy enabled complete weaning from intravenous vasopressors within 5 days.
  • The patient was discharged home for hospice care, tolerating oral midodrine and low-dose carvedilol.
  • This suggests midodrine can be effective in managing refractory hypotension in select advanced HF patients.

Implications:

  • Midodrine presents a viable oral alternative for managing refractory hypotension in advanced heart failure patients.
  • It may help reduce the need for prolonged intravenous vasoactive support in non-transplant candidates.
  • Further research is warranted to explore midodrine's role in advanced heart failure management.